leisure time -WSS

leisure time

author：leisure time 2025-10-01 15:30:51 - browse：42637

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： White House drug shortages task force keeps mum with Congress

WSS

GOP presidential candidates start declaring their loyalty

Insmed lung disease drug hits target in key Phase 3 trial

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Timeline: Special counsel's investigation into Trump's handling of classified documents

hotspot

leisure time

entertainment

The high cost of giving birth even with insurance

Heat waves linked to early deliveries, preterm births in new study

Novavax promises a turnaround & Lilly roils the obesity market

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Walensky prepares to leave CDC — and Congress — behind

Average age of first period drops to 11.9 years, study shows

In age of alternative facts, a scholarly course on calling out crap

Timeline: Special counsel's investigation into Trump's handling of classified documents

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Report: NIH

hotspot

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Startling documents reveal new facets of Sacklers' opioid empire

Stigma and the return of syphilis

Genentech weighs delaying cancer therapy after drug pricing law

Large hospital system sues Multiplan for low

Newly revealed memo details efforts to keep Trump in power following election loss

hotspot

leisure time

knowledge

leisure time